BTIG Maintains Buy on Haemonetics, Raises Price Target to $142
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
BTIG analyst Marie Thibault maintains Haemonetics (NYSE:HAE) with a Buy and raises the price target from $130 to $142.
BTIG analyst Marie Thibault maintains Haemonetics (NYSE:HAE) with a Buy and raises the price target from $130 to $142.